Blog for the LGBT community, informative and amusing – A new vision for the world
(No Ratings Yet)
South Africa adopts low-cost single dose antiretrovirals
(Blogmensgo, April 13, 2013) The South African government officially launched on April 8, 2013, a program to massively distribute antiretroviral single outlet. The Minister of Health , Aaron Motsoaledi Pakishe says that treatment will only cost 89 rand per patient or 7.50 euros (per month, it seems).
Each tablet contains a combination of six elements, because of one tablet per day. Will result in a significant reduction of logistics costs and bring prices down. So much so that the ARV is "the cheapest in the world," the minister said.
The Minister said that the distribution of antiretrovirals single dose will be extended from June, under the 2013-2014 fiscal year. From April 8, 2013, approximately 930,000 patients will benefit through the 3000 public clinics nationwide. This will be a first step of the new cases of HIV infection, pregnant women and nursing mothers, the Minister specifies in a statement .
Patients who are already taking antiretroviral therapy in multiple can migrate to new drugs after clinical evaluation by their physician. Will then be considered as priority patients whose viral load is undetectable and resent stavudine included in their current antiretroviral therapy.
Ultimately, new antiretrovirals are administered to an estimated 2.5 million patients through an agreement with Aspen Pharmcare laboratories, Cipla Medpro and Mylan Pharmaceuticals.
With today 6 million HIV-positive (11% of the population) with 1.9 million people on antiretrovirals, South Africa is one of the most affected by HIV / AIDS country.
The South African AIDS Council ( Sanac ) welcomes this initiative, noting that 70% of South African poz also suffer from tuberculosis and antiretroviral multiple decision undermine the effectiveness of treatment because of difficulties with respect to the dose.
This article has been translated from our French blog, to view the original, click here.